



This project is co-financed by the
European Union and the Republic of Turkey
Bu proje Avrupa Birliđi ve Türkiye Cumhuriyeti tarafından
finanse edilmektedir

Saverio Alberti

Mediterranea Theranostic

E-mail: alberti.saverio@gmail.com

mediterranea.theranostic.srl@gmail.com

Description of the Organization

- Mediterranea Theranostic (Mediterranea) is a Biotech Company based in Italy, as partnership between academic institutions and private entrepreneurs.
- Trop-2 induces tumor growth and metastasis, and is expressed by most cancer types. The mission of Mediterranea is to develop new anti-Trop-2 therapies, circulating cancer markers and related diagnostic tests. These will determine if the tumor of each individual patient expresses the therapeutic target Trop-2. They will also allow to follow the progression of the disease and monitor therapeutic efficacy.
- The new anticancer therapies will be based on proprietary anti-tumor monoclonal antibodies, which only recognize the cancer form of Trop-2 and synergize in vivo.

Description of your research interest

- Identification of cancers risk factors.
- Genetic/genomic analysis of mutations of oncogenes and tumor suppressor genes.
- Next-generation sequence analysis of transcriptome of human and experimental cancers.
- Cancer proteomic analysis.
- Multiparametric analysis of experimental cancer models and patient tumor cases series.
- Identification of biological factors of tumor progression/metastasis.
- Development of anti-neoplastic therapies (monoclonal antibodies, siRNA, recombinant molecules).

Project Idea

Call Topic of Interest

HORIZON-MISS-2021-CANCER-02-01: Develop new methods and technologies for cancer screening and early detection

HORIZON-MISS-2021-CANCER-02-03: Better understanding of the impact of risk factors and health determinants on the development and progression of cancer

Project ideas

- We discovered that Trop-2 is the only gene expressed in most metastatic cancers
- The Trop-2 protein is consistently released in the bloodstream, when a patient undergoes relapse. This will allow to follow the disease course

TITLE «Clinical validation of Trop-2 as a blood cancer biomarker »

- Objectives
 - to develop a high-throuput, proprietary, clinical-ready assay
 - to validate such biomarker in patient breast, colon, ovarian cancers
- Expected results
 - Biomarker's high specificity (100%) and high sensitivity (90%)
 - Low-cost ELISA assay

Consortium - profile of known partners

No	Partner Name	Type	Country	Role in the Project
01	Clinical collaborator		Germany	Biomarker validation in clinical settings
02	Clinical collaborator		Italy	Biomarker validation in clinical settings
03	Clinical collaborator		France	Biomarker validation in clinical settings
04				
05				
06				

Consortium - required partners

No	Expertise	Type	Country	Role in the project
01	Project coordination	PC	EC country	Project coordinator
02		SME	EC country	Clinical assay development
03		CRO	EC country	Clinical experimentation management
04				
05				
06				



This project is co-financed by the
European Union and the Republic of Turkey
Bu proje Avrupa Birliđi ve Türkiye Cumhuriyeti tarafından
finanse edilmektedir

Saverio Alberti

Mediterranea Theranostic Italy

Tel +39-347-3445123

E-mail alberti.saverio@gmail.com

mediterranea.theranostic.srl@gmail.com

Web <https://www.mediterranea-theranostic.com/en/>